Latest Reimbursement News

Anson Resources has secured a conditional US$357.7 million incentive package proposal from Utah authorities, potentially easing capital and tax burdens for its Green River Lithium Project and enhancing its financial outlook.

Canyon Resources has advanced key infrastructure for its Minim Martap bauxite project, delivering locomotives and increasing stakes in Camrail and the Port of Douala operator, while navigating a conditional takeover bid from its majority shareholder.

4DMedical has secured a pivotal three-year contract with SimonMed Imaging to deploy its CT:VQ™ lung imaging technology across over 170 US outpatient centres, while FY26 revenue rose 23% to $7.2 million on record scan volumes and global expansion.

Tissue Repair advances its US Phase III chronic wound trial with 100 patients randomised and targets October FDA 510(k) submission. The company reports a robust cash position bolstered by R&D refunds and has cut manufacturing scale-up costs.

GreenX Metals has outlined a substantial Exploration Target at its Tannenberg Copper Project in Germany, confirming its geological similarity to major Polish Kupferschiefer mines and setting the stage for active drilling and metallurgical work. Concurrently, fieldwork at the Eleonore North Project in Greenland has identified new high-priority tungsten and antimony targets, while a key legal challenge in Singapore was dismissed, affirming GreenX’s compensation rights.

EBR Systems advanced its wireless cardiac pacing rollout in Q2 2026, completing 46 implants and signing 17 new purchasing contracts while shifting focus to deeper utilisation within existing accounts.

IperionX reports steady ramp-up of titanium powder output at Virginia facility, successful commissioning of major powder metallurgy equipment, and progress in customer product development. The Titan DFS confirms strong project economics, while the Atlas acquisition broadens critical mineral resources and infrastructure.

Titan Minerals has ramped up drilling at its Dynasty Gold Project, confirming extensions to mineralisation and advancing scoping studies ahead of a resource upgrade targeted for early 2027.

OncoSil Medical reported a 53% increase in unit sales and advanced key regulatory approvals, including FDA final review and TGA listing, positioning it for growth in pancreatic cancer treatment.

BCAL Diagnostics has strengthened its leadership, advanced breast cancer detection tests, and secured key funding and strategic investments to underpin its FY2027 growth plans.

Rhythm Biosciences bolstered its financial position with a $5.2 million option underwriting while accelerating commercial adoption of its ColoSTAT® colorectal cancer test and advancing geneType™ partnerships internationally in Q4 FY26.

Epiminder has leveraged its $125 million IPO to advance clinical enrolments, boost Medicare reimbursement, and develop its next-generation Minder device, positioning for a commercial launch in early 2028.